focus -WSS

focus

author：focus 2025-10-01 04:13:53 - browse：71

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： CDC recommends rationing of RSV shot due to shortages

knowledge

Wikipedia

WSS

Meta's Zuckerberg and Chan on track to put $50 billion into science

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Biogen Alzheimer’s drug launch off to slow start

What should King Charles tell the public about his cancer?

What we’ve learned from the Aduhelm mess

Medtronic CEO on promising devices for diabetes, hypertension

Wikipedia

focus

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Medicare Advantage proposed rates disappoint insurers

Affirmative action in medical school literally saved lives

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Medicare proposal to cover medical devices draws a mixed reaction

Biden's order seeks to regulate AI risk without stifling innovation

How one medical school became remarkably diverse

Paying for Covid pills will soon shift to insurers

How to save PrEP access — and even expand it

Physician subsidies by hospitals soar in wake of No Surprises Act

Wikipedia

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Eli Lilly to pay $200M for Beam’s stake in gene

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Robert F. Kennedy is pitching centrism on health, even on abortion

Eli Lilly to pay $200M for Beam’s stake in gene

Why did Pfizer dish out millions for a Super Bowl ad?

knowledge

Wikipedia

entertainment

Wikipedia